Get the Stockscreener App
14.22
0.49%
0.07
Janux Therapeutics Inc stock is traded at $14.22, with a volume of 1.25M.
It is up +0.49% in the last 24 hours and up +1.35% over the past month.
Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. The proprietary technology of the company has enabled the development of distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr), Tumor Activated Immunomodulators (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms. The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain.
See More
Previous Close:
$14.15
Open:
$14.3
24h Volume:
1.25M
Relative Volume:
1.21
Market Cap:
$867.20M
Revenue:
$13.73M
Net Income/Loss:
$-114.48M
P/E Ratio:
-7.7207
EPS:
-1.8418
Net Cash Flow:
$-78.49M
1W Performance:
+4.10%
1M Performance:
+1.35%
6M Performance:
+1.28%
1Y Performance:
-37.41%
1-Day Range:
$13.79
$14.53
1-Week Range:
$13.53
$14.53
52-Week Range:
$12.12
$35.34
Janux Therapeutics Inc Stock (JANX) Company Profile
Name
Janux Therapeutics Inc
Sector
Industry
Phone
(858) 751-4493
Address
10955 VISTA SORRENTO PARKWAY, SAN DIEGO
Compare JANX vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
JANX
Janux Therapeutics Inc
|
14.22 | 867.20M | 13.73M | -114.48M | -78.49M | -1.8418 |
VRTX
Vertex Pharmaceuticals Inc
|
451.63 | 114.63B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
609.94 | 63.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.72 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.09 | 37.13B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
162.99 | 34.65B | 742.00K | -1.37B | -1.07B | -7.0731 |
Janux Therapeutics Inc Stock (JANX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-20-26 | Downgrade | Barclays | Overweight → Underweight |
| Apr-15-26 | Downgrade | UBS | Buy → Neutral |
| Nov-18-25 | Initiated | Wolfe Research | Peer Perform |
| Sep-17-25 | Initiated | Barclays | Overweight |
| Sep-10-25 | Initiated | Stifel | Buy |
| Sep-10-25 | Initiated | Truist | Buy |
| Sep-04-25 | Initiated | Guggenheim | Buy |
| Aug-19-25 | Initiated | Piper Sandler | Overweight |
| Jul-11-25 | Initiated | Raymond James | Outperform |
| Dec-03-24 | Reiterated | BTIG Research | Buy |
| Dec-03-24 | Reiterated | H.C. Wainwright | Buy |
| Nov-22-24 | Initiated | Leerink Partners | Outperform |
| Oct-24-24 | Initiated | UBS | Buy |
| Sep-06-24 | Initiated | Stifel | Buy |
| May-30-24 | Initiated | Scotiabank | Sector Perform |
| Mar-21-24 | Initiated | BTIG Research | Buy |
| Mar-20-24 | Initiated | Cantor Fitzgerald | Overweight |
| Apr-06-23 | Initiated | Wedbush | Outperform |
| Nov-14-22 | Initiated | William Blair | Outperform |
View All
Janux Therapeutics Inc Stock (JANX) Latest News
Janux Therapeutics Inc (JANX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Janux Therapeutics Inc (JANX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
JANX SEC FilingsJanux Therapeutics, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
Janux Therapeutics Inc (JANX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Janux Therapeutics Inc (JANX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Janux Therapeutics Inc (JANX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Janux Therapeutics Inc (JANX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Janux Therapeutics Inc (JANX) Institutional Confidence - TradingKey
Janux Therapeutics Inc (JANX) Valuation: PE, PB & Fair Value Analysis - TradingKey
Top Cybin (HELP) Competitors 2026 - MarketBeat
Behavioral Patterns of JANX and Institutional Flows - Stock Traders Daily
Janux Therapeutics (JANX) details RSU and stock option grants to RA Capital–linked entities - Stock Titan
Janux Therapeutics (JANX) director reports RSU and option awards tied to RA Capital - Stock Titan
Janux Therapeutics (JANX) awards director RSUs and 15,500 options - Stock Titan
Janux Therapeutics (JANX) director awarded RSUs and stock options - Stock Titan
Director at Janux Therapeutics (JANX) gets new RSUs and stock options - Stock Titan
Janux Therapeutics Reports Results of 2026 Annual Meeting - TipRanks
Shareholders back Janux Therapeutics (NASDAQ: JANX) board and pay - Stock Titan
Janux Therapeutics, Inc. (JANX) reports Q1 loss, lags revenue estimates - MSN
How much upside is left in Janux Therapeutics (JANX)? Wall Street analysts think 180.44% - MSN
Janux Therapeutics (JANX) Q1 2026 Earnings: Better-than-Expected Loss Reduction Highlights Pipeline ProgressNew Analyst Coverage - newsline.com
JANX News | JANUX THERAPEUTICS INC (NASDAQ:JANX) - ChartMill
B of A Securities Maintains Janux Therapeutics (JANX) Buy Recommendation - MSN
JANX Technical Analysis & Stock Price Forecast - Intellectia AI
(JANX) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
Janux Therapeutics officer Janeen Doyle sells $56,943 in stock By Investing.com - Investing.com South Africa
Janux Therapeutics officer Janeen Doyle sells $56,943 in stock - Investing.com UK
Janux Therapeutics (JANX) officer auto-sells 4,059 shares to cover RSU taxes - Stock Titan
4,059 RSUs to be Sold by JANX (NASDAQ: JANX) - Stock Titan
JANX Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
Janux Therapeutics Q1 2026 Earnings: Narrower Loss Surprises, Stock Edges LowerEarnings Power Value - thelegaladvocate.com
Janux Therapeutics, Inc.Common Stock (NQ: JANX - FinancialContent
Wall Street analysts predict a 155.82% upside in Janux Therapeutics (JANX): Here's what you should know - MSN
Wall Street Analysts Predict a 155.82% Upside in Janux Therapeutics (JANX): Here's What You Should Know - Yahoo Finance
JANX: Janux TherapeuticsPrice & Consenus Chart - Zacks Investment Research
Here's Why You Should Add JANX Stock to Your Portfolio Now - TradingView
JANX Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
How (JANX) Movements Inform Risk Allocation Models - Stock Traders Daily
Analyst Reiterates Buy on Janux Therapeutics, Citing Deep Pipeline Catalysts and Compelling Risk/Reward at Near-Zero Enterprise Value - TipRanks
JANX Q1 2026 Earnings: Narrowed Loss Beats Estimates; Clinical Pipeline Progress UnderwayManagement Tone Analysis - newsline.com
Janux secures $35 million milestone payment from Bristol Myers Squibb - MSN
Janux Therapeutics (JANX) price target decreased by 14.60% to 42.12 - MSN
Janus Henderson (JANX) discloses 4.2M shares, 6.9% passive stake - Stock Titan
Trading Systems Reacting to (JANX) Volatility - Stock Traders Daily
Janux Therapeutics Inc Stock (JANX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.74%
1.44%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):